Search

Your search keyword '"Mangla, Kamal Kant"' showing total 23 results
Start Over Author "Mangla, Kamal Kant"
23 results on '"Mangla, Kamal Kant"'

7. TOP-309 Identifying patient characteristics associated with the risk of long-term liver and cardiovascular outcomes and high healthcare costs in metabolic dysfunction-associated steatohepatitis: a retrospective cohort analysis using an artificial intelligence model

Author

Mangla, Kamal Kant, primary, Gbadamosi, Semiu, additional, Semeniuta, Daniel, additional, Soule, Benjamin, additional, Nordahl, Helene, additional, Bandaria, Jigar, additional, Zabinski, Joseph, additional, Curhan, Gary, additional, and Boussios, Costas, additional

Published
2024
Full Text
View/download PDF

9. Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis

Author

Younossi, Zobair M., primary, Mangla, Kamal Kant, additional, Berentzen, Tina Landsvig, additional, Grau, Katrine, additional, Kjær, Mette Skalshøi, additional, Ladelund, Steen, additional, Nitze, Louise Maymann, additional, Coolbaugh, Crystal, additional, Hsu, Chih-Yuan, additional, and Hagström, Hannes, additional

Published
2024
Full Text
View/download PDF

12. Risk factors for fibrosis progression in non-alcoholic steatohepatitis: analysis of the European cohort in the real-world GAIN study

Author

Shaikh, Anum, primary, Pedra, Gabriel, additional, Ruiz-Casas, Leonardo, additional, Franks, Bethany, additional, Dhillon, Harpal, additional, Fernandes, João Diogo da Rocha, additional, Mangla, Kamal Kant, additional, Augusto, Margarida, additional, Romero-Gómez, Manuel, additional, and Schattenberg, Jörn M., additional

Published
2023
Full Text
View/download PDF

14. Editorial: Feeling better about NASH—Authors' reply

Author

Romero‐Gómez, Manuel, primary, Armstrong, Matthew J., additional, Funuyet‐Salas, Jesús, additional, Mangla, Kamal Kant, additional, Ladelund, Steen, additional, Sejling, Anne‐Sophie, additional, Shrestha, Ichhya, additional, and Sanyal, Arun J., additional

Published
2023
Full Text
View/download PDF

16. Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial

Author

Novo Nordisk, Romero-Gómez, Manuel, Armstrong, Matthew J., Funuyet-Salas, Jesús, Mangla, Kamal Kant, Ladelund, Steen, Sejling, Anne-Sophie, Shrestha, Ichhya, Sanyal, Arun J., Novo Nordisk, Romero-Gómez, Manuel, Armstrong, Matthew J., Funuyet-Salas, Jesús, Mangla, Kamal Kant, Ladelund, Steen, Sejling, Anne-Sophie, Shrestha, Ichhya, and Sanyal, Arun J.

Abstract

[Background] Non-alcoholic steatohepatitis (NASH) can adversely affect health-related quality of life (HRQoL)., [Aims] This double-blind, placebo-controlled, phase 2 trial aimed to report the effects of the glucagon-like peptide-1 receptor agonist, semaglutide, on HRQoL in patients with NASH as a secondary endpoint., [Methods] Adults with biopsy-proven NASH and stage 1–3 fibrosis were randomised (3:3:3:1:1:1) to once-daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks. Patients were invited to complete the Short Form-36 version 2.0 questionnaire at weeks 0, 28, 52 and 72., [Results] Between January 2017 and September 2018, 320 patients were enrolled. At 72 weeks, semaglutide was associated with significant improvements in physical component summary (PCS) score (estimated treatment difference [ETD] 4.26; 95% confidence interval [CI]: 1.96–6.55; p = 0.0003); bodily pain (ETD 5.07; 95% CI: 2.15–7.99; p = 0.0007); physical functioning (ETD 3.51; 95% CI: 1.16–5.86; p = 0.0034); role limitations due to physical health problems (ETD 2.80; 95% CI: 0.28–5.33; p = 0.0294); social functioning (ETD 3.16; 95% CI: 0.53–5.78; p = 0.0183) and vitality (ETD 4.47; 95% CI: 1.63–7.32; p = 0.0021). There was no significant difference in the mental component summary score (ETD 1.02; 95% CI: −1.59 to 3.62; p = 0.4441). After 72 weeks, improvements in PCS scores were significantly greater in patients (pooled semaglutide and placebo) with NASH resolution than without (p = 0.014)., [Conclusions] Treatment with semaglutide is associated with improvements in the physical components of HRQoL in patients with biopsy-proven NASH and fibrosis compared with placebo. ClinicalTrials.gov: NCT02970942.

Published
2023

17. Improved health‐related quality of life with semaglutide in people with non‐alcoholic steatohepatitis: A randomised trial.

Author

Romero‐Gómez, Manuel, Armstrong, Matthew J., Funuyet‐Salas, Jesús, Mangla, Kamal Kant, Ladelund, Steen, Sejling, Anne‐Sophie, Shrestha, Ichhya, and Sanyal, Arun J.

Subjects
NON-alcoholic fatty liver disease, QUALITY of life, GLUCAGON-like peptide-1 receptor, SEMAGLUTIDE, GLUCAGON-like peptide-1 agonists, LUTEINIZING hormone releasing hormone
Abstract

Summary: Background: Non‐alcoholic steatohepatitis (NASH) can adversely affect health‐related quality of life (HRQoL). Aims: This double‐blind, placebo‐controlled, phase 2 trial aimed to report the effects of the glucagon‐like peptide‐1 receptor agonist, semaglutide, on HRQoL in patients with NASH as a secondary endpoint. Methods: Adults with biopsy‐proven NASH and stage 1–3 fibrosis were randomised (3:3:3:1:1:1) to once‐daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks. Patients were invited to complete the Short Form‐36 version 2.0 questionnaire at weeks 0, 28, 52 and 72. Results: Between January 2017 and September 2018, 320 patients were enrolled. At 72 weeks, semaglutide was associated with significant improvements in physical component summary (PCS) score (estimated treatment difference [ETD] 4.26; 95% confidence interval [CI]: 1.96–6.55; p = 0.0003); bodily pain (ETD 5.07; 95% CI: 2.15–7.99; p = 0.0007); physical functioning (ETD 3.51; 95% CI: 1.16–5.86; p = 0.0034); role limitations due to physical health problems (ETD 2.80; 95% CI: 0.28–5.33; p = 0.0294); social functioning (ETD 3.16; 95% CI: 0.53–5.78; p = 0.0183) and vitality (ETD 4.47; 95% CI: 1.63–7.32; p = 0.0021). There was no significant difference in the mental component summary score (ETD 1.02; 95% CI: −1.59 to 3.62; p = 0.4441). After 72 weeks, improvements in PCS scores were significantly greater in patients (pooled semaglutide and placebo) with NASH resolution than without (p = 0.014). Conclusions: Treatment with semaglutide is associated with improvements in the physical components of HRQoL in patients with biopsy‐proven NASH and fibrosis compared with placebo. ClinicalTrials.gov: NCT02970942. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results